Corvus Pharmaceuticals (CRVS) Income Statement & Balance Sheet → Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad) Free CRVS Stock Alerts $1.61 +0.06 (+3.87%) (As of 05/1/2024 ET) Add Compare Share Share FinancialsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Corvus Pharmaceuticals Income Statement, Balance Sheet and Cash Flow Statement→ Trump’s last act as President (Ad) Related Companies: Spero Therapeutics Financial Statements Connect Biopharma Financial Statements Tempest Therapeutics Financial Statements Aileron Therapeutics Financial Statements Marinus Pharmaceuticals Financial Statements Anebulo Pharmaceuticals Financial Statements BeyondSpring Financial Statements Journey Medical Financial Statements LifeVantage Financial Statements Vaccitech Financial Statements Receive CRVS Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:CRVS) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersAI finds its first serious applicationWall Street StarA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Report😱 This phenomenon is smashing regular market gainsMillPubProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
